BioLineRx Ltd. (NASDAQ:BLRX) Short Interest Up 28.7% in September

BioLineRx Ltd. (NASDAQ:BLRX) saw a large growth in short interest in the month of September. As of September 15th, there was short interest totalling 179,200 shares, a growth of 28.7% from the August 31st total of 139,200 shares. Based on an average daily volume of 270,600 shares, the days-to-cover ratio is currently 0.7 days.

Wall Street Analysts Forecast Growth

Separately, StockNews.com raised BioLineRx from a “sell” rating to a “hold” rating in a research report on Monday, June 3rd.

BioLineRx Stock Down 1.6 %

BioLineRx stock traded down $0.01 during midday trading on Friday, hitting $0.62. 145,924 shares of the company’s stock were exchanged, compared to its average volume of 333,238. BioLineRx has a 12 month low of $0.51 and a 12 month high of $2.03. The company has a debt-to-equity ratio of 1.34, a quick ratio of 1.49 and a current ratio of 1.61. The company has a market cap of $49.56 million, a PE ratio of -0.82 and a beta of 1.46. The firm has a 50-day moving average of $0.69 and a two-hundred day moving average of $0.73.

BioLineRx (NASDAQ:BLRX) last issued its quarterly earnings data on Thursday, August 15th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.09. The business had revenue of $5.39 million for the quarter, compared to analysts’ expectations of $3.93 million. As a group, analysts expect that BioLineRx will post -0.25 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in BioLineRx stock. PVG Asset Management Corp acquired a new stake in shares of BioLineRx Ltd. (NASDAQ:BLRX) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 123,580 shares of the biotechnology company’s stock, valued at approximately $70,000. PVG Asset Management Corp owned approximately 0.15% of BioLineRx at the end of the most recent reporting period. 1.56% of the stock is currently owned by institutional investors and hedge funds.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.